OrisDX’s Post

Some really interesting points discussed in this interview with Hemmel Amrania PhD, CEO of Digistain (a digital solution to cancer grading and prognosis) highlighting how MedTech innovation can lead to early diagnosis and improve patient outcomes through quick and efficient results delivery. With October being #BreastCancerAwarenessMonth it's exciting to see new technology coming out in this area. https://buff.ly/4e0Vv1b

We need to talk about HER2 staining. Promising treatments for patients depend on the evaluation of this stain. Yet, lab-internal quality control mostly doesn’t happen in a way, that intensity changes can be caught. But those changes are enough to shift evaluation results a score up or down. You don’t know how consistent your stain is. Until you measure it! Check out the paper to learn more.

Psyched to attend the EACR Liquid Biopsies Conference in Lyon from November 12-14, 2024! With liquid biopsies playing a growing role in cancer management — early detection, treatment monitoring, efficacy prediction, to name a few — I'm particularly curious to hear experts cover: 1. Breakthroughs in detecting various circulating analytes (cfDNA/RNA, CTCs, extracellular vesicles, etc) to the level of unprecedented sensitivities and specificities; 2. Challenges in integrating multi-modal assays into clinical practice and overcoming regulatory implementation hurdles. See you there! #EACR2024 #LiquidBiopsy #CancerResearch #CRUK

This brief article proposes a method of ctDNA detection that could be leveraged to enable inexpensive, non-invasive, over-the-counter, at-home testing for early stage cancer detection and make it easily accessible to everyone. The goal is to indiscriminately and inexpensively target a wide range of cancer types as opposed to a single variant. Currently there are some companies offering liquid biopsy testing, but they are generally unaffordable and require laboratory analysis. This work is the first of many results to come from a recursive prompting framework I am working on that leverages LLM technologies to rapidly accelerate research efforts and catalyze problem solving as a whole. As always, constructive feedback is always appreciated and I look forward to sharing more soon. #CancerDetection #EarlyCancerDetection #Nanotechnology #CancerReseearch

📅 SAVE THE DATE: September 12th, 9AM EST Join us and our partners at Revvity for an exclusive webinar featuring top experts Dr. Martin Engel from Inventia and Dr. James Hunt from Revvity, as we dive into the world of Phenotypic Profiling. 🔍 What You’ll Learn: - Cutting-edge techniques in 3D cancer culture integration with cell painting and high-content imaging - Simplified workflows with minimal protocol adjustments - How these advancements are driving actionable insights in drug discovery Secure your spot now and stay ahead in drug discovery: https://lnkd.in/g9EmFuH6 #DrugDiscovery #3DModeling

The Start of a New Era for Companion Diagnostics and Precision Medicines! #PrecisionMedicine #Oncology #CancerDiagnostics #AnatomicPathology #PrecisionDx #CompanionDx #CDx

New Research alert 💡 A study led by Maaike-Anna Hempenius et al. evaluates the consistency of HER2-low detection in breast cancer across 35 Dutch labs.     Using standardized cell lines covering the dynamic range of HER2 expression and a calibrator with Visiopharm's Qualitopix™ software to quantify the respective staining intensities, the team analyzed the HER2 staining variability, revealing a pressing need for assay standardization.    Accurate detection of HER2-low levels is vital for identifying patients eligible for trastuzumab-deruxtecan treatment.    Read the article and discover how Qualitopix can enhance HER2 staining consistency: https://lnkd.in/d7z7KKh5 Shout out to all the authors: Maaike-Anna Hempenius, Maran Eenkhoorn, Henrik Høeg, David J Dabbs, Bert van der Vegt,  Seshi R Sompuram, Nils 't Hart And our partners: HistoCyte Laboratories Ltd (HER2-specific dynamic range cell lines) Boston Cell Standards (IHC calibrators). #StayConsistent #BreastCancerAwarenessMonth #Qualitopix

From initial concept to reality! Yesterday, Dr. Dalit Porat Ben Amy presented Oralyze, a groundbreaking AI-powered oral cancer detection system, at Startup Nation Central Healthcare Innovation Centers Conference. This success story highlights how AIR's innovation ecosystem helped transform our Head of Oral Medicine's clinical expertise into healthcare technology. By bridging clinical excellence with innovation support, she developed a solution that could revolutionize oral cancer diagnostics. Looking to explore partnership opportunities? Find more here >> Airtzmc.co.il  #MedicalInnovation #HealthcareTechnology #Innovation #AI

Low dose radiation and tissue softness. How can they be interconnected? Let’s read more about this topic in the article.

The fight against cancer has seen remarkable strides in recent years, thanks to a powerful blend of innovation, collaboration, and technology. The World Economic Forum recently highlighted several groundbreaking advancements in cancer treatment and diagnosis that demonstrate the future of personalized, accessible, and highly effective care. From precision oncology that tailors treatments based on an individual's genetic profile to AI-driven diagnostic tools that enhance early detection, these developments mark a pivotal shift. Each breakthrough not only reflects years of dedicated research but also underscores the immense potential we have when industries, healthcare systems, and technology leaders come together with a shared mission. #celbrea #earlydetection #breastcancerawareness